Global Dengue Vaccine Market Analysis 2017 - Forecast to 2022

  • ID: 4301716
  • Report
  • Region: Global
  • 167 pages
  • Hoovers Research
1 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline plc
  • Panacea Biotech Ltd
  • Sanofi Pasteur
  • U.S NIH
  • Vabiotec (Vietnam)
  • MORE
The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Dengue Vaccine". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2014 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.
Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:
  • Market Sizing estimations and forecasts for 6 years across the given market segments
  • Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities,)
  • Strategic recommendations in key business segments based on the market estimations
  • Regional and country level market analysis
  • Competitive landscaping of major market players
  • Company profiling covering the financials, recent activities and the future strategies
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline plc
  • Panacea Biotech Ltd
  • Sanofi Pasteur
  • U.S NIH
  • Vabiotec (Vietnam)
  • MORE
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Dengue Vaccine Market by Vaccine Type
5.1 Introduction
5.2 Live-Attenuated Vaccines
5.2.1 CYD-TDV
5.2.2 DENVax
5.2.3 TV-003
5.3 Purified inactivated vaccine candidates
5.3.1 DEN-80E
5.3.2 TDENV-PIV
5.4 Vaccines in Preclinical Development
5.4.1 Virus-Vectored
5.4.2 VLP-based Vaccines
5.5 DNA-based Dengue Virus Vaccines
5.6 Recombinant Subunit Dengue Virus Vaccines

6 Dengue Vaccine Market by End User
6.1 Introduction
6.2 Government Institutions
6.3 NGOs
6.4 Hospitals

7 Geographical Segmentation
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 RoW
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa
7.4.4 Others

8 Vendor Landscaping
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiles
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 SWOT Analysis
9.1.3 Financial Overview
9.1.4 Strategy
9.1.5 Key Activities
9.2 Takeda Pharmaceutical company Ltd
9.3 GlaxoSmithKline plc
9.4 Merck & Co Pharmaceutical company Ltd
9.5 U.S NIH
9.6 Instituto Butantan(Brezil)
9.7 Vabiotec (Vietnam)
9.8 Sun Pharmaceutical Industries
9.9 Biological E. Limited
9.10 Panacea Biotech Ltd

10 Appendix

11 Disclaimer

List of Tables
Table 1 Global Dengue Vaccine Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Dengue Vaccine Market Analysis, by Vaccine Type, 2013-2022 ($MN)
Table 3 Global Dengue Vaccine Market Analysis, by Live-Attenuated Vaccines, 2013-2022 ($MN)
Table 4 Global Dengue Vaccine Market Analysis, by CYD-TDV, 2013-2022 ($MN)
Table 5 Global Dengue Vaccine Market Analysis, by DENVax, 2013-2022 ($MN)
Table 6 Global Dengue Vaccine Market Analysis, by TV-003, 2013-2022 ($MN)
Table 7 Global Dengue Vaccine Market Analysis, by Purified Inactivated Vaccine Candidates, 2013-2022 ($MN)
Table 8 Global Dengue Vaccine Market Analysis, by DEN-80E, 2013-2022 ($MN)
Table 9 Global Dengue Vaccine Market Analysis, by TDENV-PIV, 2013-2022 ($MN)
Table 10 Global Dengue Vaccine Market Analysis, by Vaccines in Preclinical Development, 2013-2022 ($MN)
Table 11 Global Dengue Vaccine Market Analysis, by Virus-Vectored, 2013-2022 ($MN)
Table 12 Global Dengue Vaccine Market Analysis, by VLP-based vaccines, 2013-2022 ($MN)
Table 13 Global Dengue Vaccine Market Analysis, by DNA-based Dengue Virus Vaccines, 2013-2022 ($MN)
Table 14 Global Dengue Vaccine Market Analysis, by Recombinant Subunit Dengue Virus Vaccines, 2013-2022 ($MN)
Table 15 Global Dengue Vaccine Market Analysis, by End User, 2013-2022 ($MN)
Table 16 Global Dengue Vaccine Market Analysis, by Government Institutions, 2013-2022 ($MN)
Table 17 Global Dengue Vaccine Market Analysis, by NGOs, 2013-2022 ($MN)
Table 18 Global Dengue Vaccine Market Analysis, by Hospitals, 2013-2022 ($MN)
Table 19 North America Dengue Vaccine Market Analysis, by Country, 2013-2022 ($MN)
Table 20 North America Dengue Vaccine Market Analysis, by Vaccine Type, 2013-2022 ($MN)
Table 21 North America Dengue Vaccine Market Analysis, by Live-Attenuated Vaccines, 2013-2022 ($MN)
Table 22 North America Dengue Vaccine Market Analysis, by CYD-TDV, 2013-2022 ($MN)
Table 23 North America Dengue Vaccine Market Analysis, by DENVax, 2013-2022 ($MN)
Table 24 North America Dengue Vaccine Market Analysis, by TV-003, 2013-2022 ($MN)
Table 25 North America Dengue Vaccine Market Analysis, by Purified Inactivated Vaccine Candidates, 2013-2022 ($MN)
Table 26 North America Dengue Vaccine Market Analysis, by DEN-80E, 2013-2022 ($MN)
Table 27 North America Dengue Vaccine Market Analysis, by TDENV-PIV, 2013-2022 ($MN)
Table 28 North America Dengue Vaccine Market Analysis, by Vaccines in Preclinical Development, 2013-2022 ($MN)
Table 29 North America Dengue Vaccine Market Analysis, by Virus-Vectored, 2013-2022 ($MN)
Table 30 North America Dengue Vaccine Market Analysis, by VLP-based vaccines, 2013-2022 ($MN)
Table 31 North America Dengue Vaccine Market Analysis, by DNA-based Dengue Virus Vaccines, 2013-2022 ($MN)
Table 32 North America Dengue Vaccine Market Analysis, by Recombinant Subunit Dengue Virus Vaccines, 2013-2022 ($MN)
Table 33 North America Dengue Vaccine Market Analysis, by End User, 2013-2022 ($MN)
Table 34 North America Dengue Vaccine Market Analysis, by Government Institutions, 2013-2022 ($MN)
Table 35 North America Dengue Vaccine Market Analysis, by NGOs, 2013-2022 ($MN)
Table 36 North America Dengue Vaccine Market Analysis, by Hospitals, 2013-2022 ($MN)
Table 37 Europe Dengue Vaccine Market Analysis, by Country, 2013-2022 ($MN)
Table 38 Europe Dengue Vaccine Market Analysis, by Vaccine Type, 2013-2022 ($MN)
Table 39 Europe Dengue Vaccine Market Analysis, by Live-Attenuated Vaccines, 2013-2022 ($MN)
Table 40 Europe Dengue Vaccine Market Analysis, by CYD-TDV, 2013-2022 ($MN)
Table 41 Europe Dengue Vaccine Market Analysis, by DENVax, 2013-2022 ($MN)
Table 42 Europe Dengue Vaccine Market Analysis, by TV-003, 2013-2022 ($MN)
Table 43 Europe Dengue Vaccine Market Analysis, by Purified Inactivated Vaccine Candidates, 2013-2022 ($MN)
Table 44 Europe Dengue Vaccine Market Analysis, by DEN-80E, 2013-2022 ($MN)
Table 45 Europe Dengue Vaccine Market Analysis, by TDENV-PIV, 2013-2022 ($MN)
Table 46 Europe Dengue Vaccine Market Analysis, by Vaccines in Preclinical Development, 2013-2022 ($MN)
Table 47 Europe Dengue Vaccine Market Analysis, by Virus-Vectored, 2013-2022 ($MN)
Table 48 Europe Dengue Vaccine Market Analysis, by VLP-based vaccines, 2013-2022 ($MN)
Table 49 Europe Dengue Vaccine Market Analysis, by DNA-based Dengue Virus Vaccines, 2013-2022 ($MN)
Table 50 Europe Dengue Vaccine Market Analysis, by Recombinant Subunit Dengue Virus Vaccines, 2013-2022 ($MN)
Table 51 Europe Dengue Vaccine Market Analysis, by End User, 2013-2022 ($MN)
Table 52 Europe Dengue Vaccine Market Analysis, by Government Institutions, 2013-2022 ($MN)
Table 53 Europe Dengue Vaccine Market Analysis, by NGOs, 2013-2022 ($MN)
Table 54 Europe Dengue Vaccine Market Analysis, by Hospitals, 2013-2022 ($MN)
Table 55 Asia Pacific Dengue Vaccine Market Analysis, by Country, 2013-2022 ($MN)
Table 56 Asia Pacific Dengue Vaccine Market Analysis, by Vaccine Type, 2013-2022 ($MN)
Table 57 Asia Pacific Dengue Vaccine Market Analysis, by Live-Attenuated Vaccines, 2013-2022 ($MN)
Table 58 Asia Pacific Dengue Vaccine Market Analysis, by CYD-TDV, 2013-2022 ($MN)
Table 59 Asia Pacific Dengue Vaccine Market Analysis, by DENVax, 2013-2022 ($MN)
Table 60 Asia Pacific Dengue Vaccine Market Analysis, by TV-003, 2013-2022 ($MN)
Table 61 Asia Pacific Dengue Vaccine Market Analysis, by Purified Inactivated Vaccine Candidates, 2013-2022 ($MN)
Table 62 Asia Pacific Dengue Vaccine Market Analysis, by DEN-80E, 2013-2022 ($MN)
Table 63 Asia Pacific Dengue Vaccine Market Analysis, by TDENV-PIV, 2013-2022 ($MN)
Table 64 Asia Pacific Dengue Vaccine Market Analysis, by Vaccines in Preclinical Development, 2013-2022 ($MN)
Table 65 Asia Pacific Dengue Vaccine Market Analysis, by Virus-Vectored, 2013-2022 ($MN)
Table 66 Asia Pacific Dengue Vaccine Market Analysis, by VLP-based vaccines, 2013-2022 ($MN)
Table 67 Asia Pacific Dengue Vaccine Market Analysis, by DNA-based Dengue Virus Vaccines, 2013-2022 ($MN)
Table 68 Asia Pacific Dengue Vaccine Market Analysis, by Recombinant Subunit Dengue Virus Vaccines, 2013-2022 ($MN)
Table 69 Asia Pacific Dengue Vaccine Market Analysis, by End User, 2013-2022 ($MN)
Table 70 Asia Pacific Dengue Vaccine Market Analysis, by Government Institutions, 2013-2022 ($MN)
Table 71 Asia Pacific Dengue Vaccine Market Analysis, by NGOs, 2013-2022 ($MN)
Table 72 Asia Pacific Dengue Vaccine Market Analysis, by Hospitals, 2013-2022 ($MN)
Table 73 RoW Dengue Vaccine Market Analysis, by Country, 2013-2022 ($MN)
Table 74 RoW Dengue Vaccine Market Analysis, by Vaccine Type, 2013-2022 ($MN)
Table 75 RoW Dengue Vaccine Market Analysis, by Live-Attenuated Vaccines, 2013-2022 ($MN)
Table 76 RoW Dengue Vaccine Market Analysis, by CYD-TDV, 2013-2022 ($MN)
Table 77 RoW Dengue Vaccine Market Analysis, by DENVax, 2013-2022 ($MN)
Table 78 RoW Dengue Vaccine Market Analysis, by TV-003, 2013-2022 ($MN)
Table 79 RoW Dengue Vaccine Market Analysis, by Purified Inactivated Vaccine Candidates, 2013-2022 ($MN)
Table 80 RoW Dengue Vaccine Market Analysis, by DEN-80E, 2013-2022 ($MN)
Table 81 RoW Dengue Vaccine Market Analysis, by TDENV-PIV, 2013-2022 ($MN)
Table 82 RoW Dengue Vaccine Market Analysis, by Vaccines in Preclinical Development, 2013-2022 ($MN)
Table 83 RoW Dengue Vaccine Market Analysis, by Virus-Vectored, 2013-2022 ($MN)
Table 84 RoW Dengue Vaccine Market Analysis, by VLP-based vaccines, 2013-2022 ($MN)
Table 85 RoW Dengue Vaccine Market Analysis, by DNA-based Dengue Virus Vaccines, 2013-2022 ($MN)
Table 86 RoW Dengue Vaccine Market Analysis, by Recombinant Subunit Dengue Virus Vaccines, 2013-2022 ($MN)
Table 87 RoW Dengue Vaccine Market Analysis, by End User, 2013-2022 ($MN)
Table 88 RoW Dengue Vaccine Market Analysis, by Government Institutions, 2013-2022 ($MN)
Table 89 RoW Dengue Vaccine Market Analysis, by NGOs, 2013-2022 ($MN)
Table 90 RoW Dengue Vaccine Market Analysis, by Hospitals, 2013-2022 ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biological E. Limited
  • GlaxoSmithKline plc
  • Instituto Butantan(Brezil)
  • Merck & Co Pharmaceutical company Ltd
  • Panacea Biotech Ltd
  • Sanofi Pasteur
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical company Ltd
  • U.S NIH
  • Vabiotec (Vietnam)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll